dabigatran etexilate mesylate - Profile

What are the generic sources for dabigatran etexilate mesylate and what is the scope of freedom to operate?

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alembic, Alkem Labs Ltd, Apotex, Aurobindo Pharma, Breckenridge, Dr Reddys, Hetero Labs Ltd Iii, MSN, Mylan, and Boehringer Ingelheim, and is included in eleven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Dabigatran etexilate mesylate has one hundred and twenty-two patent family members in forty-five countries.

There are three tentative approvals for this compound.

Summary for dabigatran etexilate mesylate

International Patents:	122
US Patents:	2
Tradenames:	2
Applicants:	10
NDAs:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dabigatran etexilate mesylate

Generic filers with tentative approvals for DABIGATRAN ETEXILATE MESYLATE

Applicant	Application No.	Strength	Dosage Form
		EQ 150MG BASE	CAPSULE;ORAL
		EQ 110MG BASE	CAPSULE;ORAL
		EQ 75MG BASE	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DABIGATRAN ETEXILATE MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRADAXA	Capsules	dabigatran etexilate mesylate	eq. to 110 mg base	022512	2	2015-12-15
PRADAXA	Capsules	dabigatran etexilate mesylate	eq. to 75 mg base and 150 mg base	022512	17	2014-10-20

US Patents and Regulatory Information for dabigatran etexilate mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	215233-001	Jun 14, 2024	AB	RX	No	No
Alembic	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	215233-003	Aug 12, 2024	AB	RX	No	No
Alembic	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	215233-002	Jun 14, 2024	AB	RX	No	No
Alkem Labs Ltd	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208040-001	Mar 11, 2020	AB	RX	No	No
Alkem Labs Ltd	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208040-003	Sep 11, 2024	AB	RX	No	No
Alkem Labs Ltd	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208040-002	Mar 11, 2020	AB	RX	No	No
Apotex	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208070-001	Dec 15, 2023	AB	RX	No	No

International Patents for dabigatran etexilate mesylate

Country	Patent Number	Title	Estimated Expiration
Philippines	12012501493	ANTICOAGULANT ANTIDOTES
Mexico	2012008360	ANTIDOTOS DE ANTICOAGULANTES. (ANTICOAGULANT ANTIDOTES.)
Singapore	145734	3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1- METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDINE-2-YL-AMINO]-PROPIONIC ACID ETHYL ESTER METHANE SULPHONATE AND USE THEREOF AS A MEDICAMENT
Norway	20061420
Australia	2004274139	3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
Israel	219427
Poland	2060569

Supplementary Protection Certificates for dabigatran etexilate mesylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0966454	SPC/GB08/037	United Kingdom		PRODUCT NAME: DABIGATRAN ETEXILATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY DABIGATRAN ETEXILATE MESYLATE; REGISTERED: UK EU/1/08/442/001 20080318; UK EU/1/08/442/002 20080318; UK EU/1/08/442/003 20080318; UK EU/1/08/442/004 20080318; UK EU/1/08/442/005 20080318; UK EU/1/08/442/006 20080318; UK EU/1/08/442/007 20080318; UK EU/1/08/442/008 20080318
2525812	122017000046	Germany		PRODUCT NAME: LDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056 20151120
1485094	132012902112338	Italy		PRODUCT NAME: DABIGATRAN ETEXILATO MESILATO(PRADAXA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/08/442/009-011-012-013-014, 20110801
0966454	SZ 19/2008	Austria		PRODUCT NAME: DABIGATRANETEXILAT UND DESSEN SALZE, INSBESONDERE DABIGATRANETEXILAT-MESILAT
2525812	283 14-2017	Slovakia		PRODUCT NAME: IDARUCIZUMAB; REGISTRATION NO/DATE: EU/1/15/1056 20151124
2525812	627	Finland
1485094	122012000103	Germany		PRODUCT NAME: DABIGATRANETEXILAT-MESYLAT; REGISTRATION NO/DATE: EU/1/08/442/009-014 20110801

Dabigatran Etexilate Mesylate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Dabigatran etexilate mesylate, marketed as Pradaxa among other brands, is an oral anticoagulant indicated primarily for stroke prevention in non-valvular atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). Since its US FDA approval in 2010, dabigatran has established a significant footprint in the anticoagulant market due to its proven efficacy, ease of use, and growing patient segments. The market’s growth trajectory is influenced by demographic shifts, regulatory policies, technological advances, and competitive dynamics.

This analysis assesses the investment potential of dabigatran etexilate mesylate within the global pharmaceutical landscape, emphasizing market size, competitive environment, key drivers, risks, and future forecasts.

---

Market Size and Financial Trajectory

Global Market Valuation & Growth (2022–2028)

Metric	2022	2025 (Projected)	2028 (Projected)	CAGR (2022–2028)
Market Size	US$5.2 billion	US$8.4 billion	US$12.7 billion	8.4%

Source: Grand View Research [1], MarketsandMarkets [2]

Key Market Drivers

• Demographic Trends: Aging populations, particularly in North America and Europe, increase incidences of atrial fibrillation.

• Clinical Advantages: Oral administration, rapid onset, and fewer dietary restrictions compared to warfarin.

• Regulatory Approvals: Expanding indications boost market penetration.

• Reimbursement Policies: Favorable coverage in developed markets enhances adoption.

Revenue Segmentation (2022)

Region	Market Share	Key Drivers
North America	50%	High adoption, reimbursement
Europe	25%	Aging population, clinical guidelines
Asia-Pacific	15%	Expanding approval, increasing awareness
Rest of World	10%	Emerging markets, pipeline developments

---

Market Dynamics

Competitive Landscape

Players	Market Share (2022)	Key Attributes
Bayer / Boehringer Ingelheim	55%	Pradaxa (brand), strong brand recognition
Bristol-Myers Squibb / Pfizer	25%	Direct-acting oral anticoagulants (DOACs) portfolio
Others	20%	Generics, regional brands, new entrants

Key Competitors and Drug Portfolio

Drug	Brand / Generic	Launch Year	Indications	Market Position
Dabigatran	Pradaxa	2010 (FDA)	AFib, DVT, PE	First-mover advantage, broad adoption
Rivaroxaban	Xarelto	2011	AFib, DVT, PE	Major competitor, higher market share
Apixaban	Eliquis	2012	AFib, DVT, PE	Growing preference, safety profile

Regulatory Landscape

• United States: FDA approvals for stroke prevention in non-valvular AFib, DVT, PE.
• Europe: EMA approvals; rapid adoption aligned with guideline updates.
• Asia-Pacific: Varied approval status; recent approvals expanding market reach.
• Future Regulations: Ongoing efforts to streamline anticoagulant labeling and reimbursement.

Policy Impacts and Reimbursement Trends

• Implementation of guidelines favoring DOACs over warfarin.
• Increased reimbursement coverage in the US, EU, and select Asian markets.
• Accelerated adoption in healthcare systems prioritizing outpatient, less resource-intensive therapies.

---

Financial Trajectory and Investment Outlook

Revenue Projections and Trends

Year	Estimated Revenue (US$ Billion)	Growth Factors	Risks
2023	US$6.2	Rising ≥65 population, expanding indications	Patent expirations, generic competition
2024	US$6.8	Increased market penetration, expanding indications	Price regulation, competitive entry
2025	US$8.4	Key approvals in emerging markets, pipeline approvals	Patent cliffs, biosimilars
2026–2028	US$10–12.7	Continued demographic shifts, new formulations	Regulatory delays, pricing pressures

Key drivers include new clinical data supporting expanded indications, pipeline longevity, and strategic partnerships.

Cost and Investment Breakdown

Investment Area	% of Total Investment	Rationale
R&D	40%	Development of next-generation formulations, new indications
Regulatory Strategy	15%	Speeding approval timelines, market access
Commercialization	25%	Market expansion, physician education, reimbursement negotiations
Pipeline Development	20%	Adjuncts, combination therapies, biosimilars

---

Future Outlook and Challenges

Innovations and Pipeline Developments

• Reversal Agents: Idarucizumab is already approved. Development of universal reversal agents could further enhance safety profiles.
• Formulation Improvements: Efforts to reduce gastrointestinal side effects and improve bioavailability.
• Combination Therapies: Potential for combining dabigatran with other anticoagulants or cardiovascular agents.

Market Expansion Opportunities

• Emerging Markets: Accelerated approvals and increasing healthcare infrastructure.
• New Indications: Thrombosis in cancer patients, pediatric thrombosis.
• Digital Health Integration: Use of digital adherence tools to improve compliance.

Risks and Barriers

Risk	Description	Mitigation Strategies
Patent Expiry	Loss of exclusivity (expected around 2024–2027)	Patent challenges, lifecycle management
Competitive Entry	Biosimilar and novel agents entry	Investment in differentiation, pipeline
Regulatory Changes	New safety or efficacy standards	Proactive regulatory engagement
Pricing & Reimbursement	Cost containment policies	Demonstrating value, health economics data

---

Comparison With Alternatives

Parameter	Dabigatran	Rivaroxaban	Apixaban	Warfarin	Edoxaban
Approval Year	2010	2011	2012	1960s	2015
Indications	AFib, VTE	AFib, VTE	AFib, VTE	AFib (old standard)	VTE
Dosing Frequency	Twice daily	Once daily	Twice daily	Variable	Once daily
Reversal Agent	Idarucizumab	Andexanet alfa	Andexanet alfa	Vitamin K, PCCs	Andexanet alfa
Safety Profile	Bleeding risk manageable	Similar	Favorable	Higher bleeding risk	Similar

---

Conclusion

Investment in dabigatran etexilate mesylate presents substantial opportunities driven by demographic trends, innovative pipeline developments, and expanding indications. While patent expirations pose a challenge, ongoing technological advancements and market expansion strategies in emerging economies can offset these risks.

Strategic focus should include pipeline advancement, market diversification, and enhancing safety profiles. The drug's integral role within the anticoagulation landscape underscores its long-term value proposition for stakeholders willing to navigate competitive and regulatory challenges.

---

Key Takeaways

• The global anticoagulant market is projected to grow at over 8% CAGR through 2028, with dabigatran maintaining a significant share.
• Patent expirations and biosimilar competition are imminent risks, requiring lifecycle management strategies.
• Emerging markets offer high-growth potential, supported by evolving regulatory frameworks and increased healthcare infrastructure.
• Safety profiles, key regulators, and reimbursement policies significantly influence market dynamics.
• Continuous pipeline innovation, especially in reversal agents and combination therapies, will shape the drug’s future trajectory.

---

FAQs

1. What are the main drivers of demand for dabigatran?

Demographic aging, improved clinical outcomes, convenience over warfarin, and expanding indications such as DVT and PE are primary demand drivers.

2. How does dabigatran compare with other DOACs?

Dabigatran offers rapid onset and effective reversal with idarucizumab but faces competition from rivaroxaban and apixaban, which often feature once-daily dosing and potentially better safety profiles.

3. When is patent expiration expected, and what impact will it have?

Patent expiry is projected around 2024–2027, leading to increased generic competition and downward pressure on pricing and revenues.

4. Which regions are most promising for future growth?

Emerging markets in Asia-Pacific and Latin America, with expanding approval and healthcare infrastructure, show high potential for growth.

5. What role will pipeline developments and innovations play?

They are critical for maintaining market relevance, addressing safety concerns, and expanding indications, especially in a landscape with upcoming biosimilar and generic entrants.

---

References

[1] Grand View Research. Global Anticoagulants Market Size, Share & Trends Analysis Report. 2023.
[2] MarketsandMarkets. Anticoagulant Market by Product, Indication, Route of Administration, and Region. 2022.